Related Experiment Videos
[Invasive pulmonary aspergillosis]
P Peixinho1, T Sabino, C Duarte
1Serviço de Medicina 2, Hospital de Curry Cabral, Lisboa.
Abstract:
Aspergillosis, the most frequent of pulmonary mycosis, represents a group of varying pathogenesis diseases with the same etiological agent--Aspergillus. This fungus is a saprophyte of normal respiratory airways, but the disease occurs in immunocompromised hosts. There are several anatomo-clinical forms, but it is important to know that some could be fatal, being necessary an early diagnosis and therapy. The authors describe an Invasive Pulmonary Aspegillosis case, in a immunocompromised patient submitted to long term corticotherapy treatment. Was started with liposomal Amphotericin B, discontinued due to nephrotoxicity and substituted by Itraconazol, with clinical, laboratorial and radiologic favourable evolution, as it's proven by imagiological studies.
Insights
Invasive pulmonary aspergillosis is a serious fungal infection in immunocompromised patients. Early diagnosis and treatment with antifungals like Itraconazole are crucial for favorable outcomes.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- Aspergillosis is a common pulmonary mycosis caused by Aspergillus, affecting immunocompromised individuals.
- It presents with diverse clinical forms, some potentially fatal, necessitating prompt diagnosis and treatment.
- Invasive Pulmonary Aspergillosis (IPA) is a severe manifestation requiring effective antifungal strategies.
Observation:
- A case of IPA in an immunocompromised patient on long-term corticotherapy is presented.
- Initial treatment with liposomal Amphotericin B was halted due to nephrotoxicity.
- The patient was subsequently treated with Itraconazole.
Findings:
- The switch to Itraconazole resulted in favorable clinical, laboratory, and radiological evolution.
- Imagiological studies confirmed the positive response to Itraconazole therapy.
- This highlights the efficacy of Itraconazole in managing IPA when Amphotericin B is contraindicated.
Implications:
- This case underscores the importance of individualized antifungal selection based on patient tolerance and drug toxicity.
- It emphasizes the role of Itraconazole as a viable therapeutic option for IPA in specific clinical scenarios.
- Early and effective management is critical for improving survival and quality of life in patients with IPA.